5 reasons to prefer the MOAB-2 antibody in Alzheimer ‘s Disease research
The new pan-specific MOAB-2 is a high-titer monoclonal antibody to Aβ residues 1-4. Here are 5 main reasons that will make you choose it for your research on Alzheimer’s Disease research programs!
#1 – MOAB-2 ensures unparalleled staining quality and clear staining
MOAB-2 provides stronger reactivity and greater sensitivity than any other Aβ monoclonals previously available for research.
#2 – MOAB-2 discriminates between APP and true intraneuronal Aβ in all its forms
Aβ accumulates extracellularly as the disease progresses, making MOAB-2 the ideal reagent for studying both intraneuronal Aβ at early stages and extracellular Aβ at later stages seamlessly.
You’ll get accurate data.
#3 – MOAB-2 does not cross react with APP or APP C-terminal fragments
Unlike other monoclonals such as 6E10 and 4G8, MOAB-2 does not cross react with APP or APP C-terminal fragments, which allows you better isolation and localization of Aβ protein from APP.
#4 – MOAB-2 detects pathogenic Aβ42 over Aβ40
In dot blots, MOAB-2 recognizes all forms (unaggregated, oligometric, and fibrillar) of Aβ 42 protein and the unaggregated form of AB40. MOAB-2 is selective for the more neurotoxic Aβ42 compared to Aβ40. In titration tests, MOAB-2 demonstrated 25 fold greater sensitivity of detection for the U-, O- and F-Aβ42 forms than for Aβ40.
This will allow you to work on the localization and function of Aβ42.
#5 – MOAB-2 belongs to the tebu-bio’s “satisfy or refund” Antibody Program
A large number of qualified primary antibodies are available at tebu-bio. They are all 100% guaranteed for their applications. This is also true for the monoclonal MOAB-2 for research teams keen to use this monoclonal for WB, IHC, IHC (P), IP, IF and ELISA in AD and neurobiology studies.
Get your 100-µg MOAB-2 by following this link.